ANI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANIP)

$63.75 0.81 (1.29 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$62.94
Today's Range$62.37 - $64.07
52-Week Range$42.23 - $65.81
Volume60,486 shs
Average Volume133,243 shs
Market Capitalization$723.15 million
P/E Ratio19.12
Dividend YieldN/A
Beta2.84

About ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals logoANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Biotechnology & Medical Research - NEC
  • Symbol: NASDAQ:ANIP
  • Previous Symbol: NASDAQ:BPAX
  • CUSIP: N/A
  • Web: www.anipharmaceuticals.com
Debt:
  • Debt-to-Equity Ratio: 0.83%
  • Current Ratio: 3.45%
  • Quick Ratio: 2.39%
Price-To-Earnings:
  • Trailing P/E Ratio: 19.12
  • Forward P/E Ratio: 17.76
Sales & Book Value:
  • Annual Sales: $128.62 million
  • Price / Sales: 5.77
  • Cash Flow: $4.52 per share
  • Price / Cash: 14.09
  • Book Value: $15.69 per share
  • Price / Book: 4.06
Profitability:
  • Trailing EPS: $0.63
  • Net Income: $3.93 million
  • Net Margins: 4.45%
  • Return on Equity: 22.40%
  • Return on Assets: 11.14%
Misc:
  • Employees: 143
  • Outstanding Shares: 11,650,000
 
Frequently Asked Questions for ANI Pharmaceuticals (NASDAQ:ANIP)

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its quarterly earnings data on Thursday, November, 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.99 by $0.12. The specialty pharmaceutical company earned $48.16 million during the quarter, compared to analysts' expectations of $48.12 million. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The firm's revenue for the quarter was up 25.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.09 earnings per share. View ANI Pharmaceuticals' Earnings History.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY17 earnings guidance on Thursday, November, 2nd. The company provided earnings per share guidance of $3.83-4.00 for the period, compared to the Thomson Reuters consensus estimate of $3.84. The company issued revenue guidance of $182.10 million, compared to the consensus revenue estimate of prior $3.58-3.94.

Where is ANI Pharmaceuticals' stock going? Where will ANI Pharmaceuticals' stock price be in 2017?

3 Wall Street analysts have issued 12-month target prices for ANI Pharmaceuticals' shares. Their forecasts range from $56.00 to $80.00. On average, they anticipate ANI Pharmaceuticals' stock price to reach $67.33 in the next twelve months. View Analyst Ratings for ANI Pharmaceuticals.

What are Wall Street analysts saying about ANI Pharmaceuticals stock?

Here are some recent quotes from research analysts about ANI Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. " (11/7/2017)
  • 2. Canaccord Genuity analysts commented, "We remain pessimistic about the company’s ability to execute a successful clinical trial required for FDA approval. The planned 2018 $10M cost-cutting initiative suggests to us that Eagle isn’t too confident either (and is generally in line with our expectations). Eagle’s other pipeline programs like fulvestrant and drug-induced hyperthermia are questionable and may require a few more years of development under a best case scenario, in our view. There was strangely no mention of the Alimta RTD PDUFA in October. Eagle also reiterated prior 2017 expense guidance of $50-$53M in SG&A (excluding stock based comp) and $26- $30M R&D (excluding stock-based comp). We note the company was previously reporting GAAP earnings so the change is slightly new. We also note that Eagle has expanded its borrowing capacity by $100M (suggesting to us that it may want to bring in new assets) but simultaneously announced an additional $100M buyback program." (8/9/2017)

Who are some of ANI Pharmaceuticals' key competitors?

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the folowing people:

  • Robert E. Brown Jr., Independent Chairman of the Board (Age 66)
  • Arthur S. Przybyl, President, Chief Executive Officer, Director (Age 60)
  • Stephen P. Carey, Chief Financial Officer, Vice President (Age 46)
  • James G. Marken, Vice President - Operations (Age 54)
  • Mark J. Ginski Ph.D., Vice President of Corticotropin Product Development
  • Karen Quinn Ph.D., Vice President - Corticotropin Regulatory Affairs
  • Robert W. Schrepfer, Vice President - New Business Development and Contract Manufacturing (Age 45)
  • Fred E. Holubow, Independent Director (Age 78)
  • Tracy L. Marshbanks Ph.D., Independent Director (Age 53)
  • Thomas A. Penn, Independent Director (Age 71)

Who owns ANI Pharmaceuticals stock?

ANI Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (3.65%), First Manhattan Co. (3.21%), JPMorgan Chase & Co. (0.90%), Principal Financial Group Inc. (0.58%), Skandinaviska Enskilda Banken AB publ (0.47%) and Schwab Charles Investment Management Inc. (0.40%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, James G Marken and Robert W Schrepfer. View Institutional Ownership Trends for ANI Pharmaceuticals.

Who sold ANI Pharmaceuticals stock? Who is selling ANI Pharmaceuticals stock?

ANI Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors, Wells Fargo & Company MN, First Manhattan Co., Perkins Capital Management Inc. and California State Teachers Retirement System. View Insider Buying and Selling for ANI Pharmaceuticals.

Who bought ANI Pharmaceuticals stock? Who is buying ANI Pharmaceuticals stock?

ANI Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Dimensional Fund Advisors LP, Cadence Capital Management LLC, Skandinaviska Enskilda Banken AB publ, ETRADE Capital Management LLC, Dupont Capital Management Corp, Campbell & CO Investment Adviser LLC and Stifel Financial Corp. View Insider Buying and Selling for ANI Pharmaceuticals.

How do I buy ANI Pharmaceuticals stock?

Shares of ANI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ANI Pharmaceuticals' stock price today?

One share of ANI Pharmaceuticals stock can currently be purchased for approximately $63.75.

How big of a company is ANI Pharmaceuticals?

ANI Pharmaceuticals has a market capitalization of $723.15 million and generates $128.62 million in revenue each year. The specialty pharmaceutical company earns $3.93 million in net income (profit) each year or $0.63 on an earnings per share basis. ANI Pharmaceuticals employs 143 workers across the globe.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 W Main St, BAUDETTE, MN 56623-2467, United States. The specialty pharmaceutical company can be reached via phone at +1-218-6343500 or via email at ir@anipharmaceuticals.com.


MarketBeat Community Rating for ANI Pharmaceuticals (NASDAQ ANIP)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  180 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for ANI Pharmaceuticals (NASDAQ:ANIP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $67.33 (5.62% upside)
Consensus Price Target History for ANI Pharmaceuticals (NASDAQ:ANIP)
Price Target History for ANI Pharmaceuticals (NASDAQ:ANIP)
Analysts' Ratings History for ANI Pharmaceuticals (NASDAQ:ANIP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/2/2017Canaccord GenuityReiterated RatingBuyN/AView Rating Details
7/4/2017GuggenheimReiterated RatingBuy$80.00LowView Rating Details
5/6/2017Roth CapitalSet Price TargetHold$56.00LowView Rating Details
8/5/2016Oppenheimer Holdings, Inc.Boost Price TargetOutperform$65.00 -> $71.00N/AView Rating Details
7/19/2016Citigroup Inc.UpgradeOutperform$65.00N/AView Rating Details
6/22/2016Raymond James Financial, Inc.Initiated CoverageStrong-Buy$68.00N/AView Rating Details
5/24/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for ANI Pharmaceuticals (NASDAQ:ANIP)
Earnings by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
Earnings History by Quarter for ANI Pharmaceuticals (NASDAQ ANIP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017$0.99$1.11$48.12 million$48.16 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.79$0.98$43.20 million$44.80 millionViewListenView Earnings Details
5/4/2017Q1 2017$0.70$0.74$39.63 million$36.60 millionViewListenView Earnings Details
3/2/2017Q4 2016$1.09$0.84$40.98 million$38.20 millionViewListenView Earnings Details
11/3/2016Q316$1.08$1.09$34.34 million$38.53 millionViewN/AView Earnings Details
8/4/2016Q216$0.77$1.11$27.63 million$31.30 millionViewN/AView Earnings Details
5/5/2016Q116$0.64$0.76$21.03 million$20.60 millionViewN/AView Earnings Details
2/23/2016Q415$0.60$0.52$18.13 million$18.04 millionViewN/AView Earnings Details
11/3/2015Q315$0.63$0.80$21.37 million$20.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.54$0.31$20.30 million$19.52 millionViewN/AView Earnings Details
5/5/2015Q115$0.56$0.53$19.86 million$18.80 millionViewN/AView Earnings Details
2/19/2015Q414$0.57$0.60$17.98 million$21.04 millionViewN/AView Earnings Details
11/3/2014Q314$0.43$0.59$14.60 million$17.40 millionViewN/AView Earnings Details
8/4/2014Q214($0.01)($0.21)$7.95 million$6.60 millionViewN/AView Earnings Details
5/5/2014Q115$0.32$0.33$11.40 million$10.90 millionViewN/AView Earnings Details
2/27/2014Q414$0.35$5.32 million$10.53 millionViewN/AView Earnings Details
11/7/2013$0.16ViewN/AView Earnings Details
11/8/2012Q312($0.36)($0.27)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ANI Pharmaceuticals (NASDAQ:ANIP)
Current Year EPS Consensus Estimate: $3.59 EPS
Next Year EPS Consensus Estimate: $4.35 EPS

Dividends

Dividend History for ANI Pharmaceuticals (NASDAQ:ANIP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ANI Pharmaceuticals (NASDAQ ANIP)
Insider Ownership Percentage: 31.80%
Institutional Ownership Percentage: 56.48%
Insider Trades by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
Insider Trades by Quarter for ANI Pharmaceuticals (NASDAQ ANIP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2016Arthur PrzybylInsiderSell37,455$66.97$2,508,361.35View SEC Filing  
8/8/2016Robert W SchrepferVPSell12,500$67.06$838,250.00View SEC Filing  
12/18/2015James G MarkenVPSell3,500$43.26$151,410.00View SEC Filing  
11/12/2015Arthur PrzybylCEOBuy2,500$40.95$102,375.00View SEC Filing  
3/19/2015James G MarkenVPSell15,000$66.50$997,500.00View SEC Filing  
9/15/2014Ross J ManganoDirectorBuy3,000$27.49$82,470.00View SEC Filing  
9/9/2014Arthur PrzybylCEOBuy1,000$26.50$26,500.00View SEC Filing  
6/18/2014James G MarkenVPSell5,000$34.28$171,400.00View SEC Filing  
5/8/2014Tracy MarshbanksDirectorSell1,381$30.02$41,457.62View SEC Filing  
5/7/2014Ross ManganoDirectorBuy2,000$30.38$60,760.00View SEC Filing  
3/21/2014Tracy MarshbanksDirectorSell21,767$31.42$683,919.14View SEC Filing  
3/20/2014Meridian Venture Partners Ii Lmajor shareholderSell20,922$32.12$672,014.64View SEC Filing  
3/19/2014Tracy MarshbanksDirectorSell25,358$33.68$854,057.44View SEC Filing  
3/18/2014Meridian Venture Partners Ii Lmajor shareholderSell60,540$34.07$2,062,597.80View SEC Filing  
3/13/2014Meridian Venture Partners Ii Lmajor shareholderSell87,723$32.48$2,849,243.04View SEC Filing  
11/7/2013Ross J ManganoDirectorBuy9,000$11.27$101,430.00View SEC Filing  
8/20/2013Ross J ManganoDirectorBuy10,000$7.47$74,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ANI Pharmaceuticals (NASDAQ:ANIP)
Latest Headlines for ANI Pharmaceuticals (NASDAQ ANIP)
Source:
DateHeadline
ETFs with exposure to ANI Pharmaceuticals, Inc. : November 16, 2017ETFs with exposure to ANI Pharmaceuticals, Inc. : November 16, 2017
finance.yahoo.com - November 16 at 4:09 PM
Zacks: Brokerages Anticipate ANI Pharmaceuticals, Inc. (ANIP) Will Post Quarterly Sales of $52.49 MillionZacks: Brokerages Anticipate ANI Pharmaceuticals, Inc. (ANIP) Will Post Quarterly Sales of $52.49 Million
www.americanbankingnews.com - November 13 at 1:20 AM
ANI Pharmaceuticals (ANIP) versus Its Competitors Head-To-Head ComparisonANI Pharmaceuticals (ANIP) versus Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - November 11 at 1:28 AM
ANI Pharmaceuticals, Inc. (ANIP) Stock Rating Upgraded by Zacks Investment ResearchANI Pharmaceuticals, Inc. (ANIP) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 7 at 3:52 PM
Critical Review: ANI Pharmaceuticals (ANIP) versus Its PeersCritical Review: ANI Pharmaceuticals (ANIP) versus Its Peers
www.americanbankingnews.com - November 7 at 11:44 AM
ETFs with exposure to ANI Pharmaceuticals, Inc. : November 6, 2017ETFs with exposure to ANI Pharmaceuticals, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 4:42 PM
ANI Pharmaceuticals, Inc. (ANIP) Given Average Rating of "Buy" by BrokeragesANI Pharmaceuticals, Inc. (ANIP) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 5 at 1:32 AM
ANI Pharmaceuticals, Inc. (ANIP) Upgraded at ValuEngineANI Pharmaceuticals, Inc. (ANIP) Upgraded at ValuEngine
www.americanbankingnews.com - November 4 at 4:42 PM
ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 4:03 PM
ANI Pharma Narrows 2017 Guidance - Quick FactsANI Pharma Narrows 2017 Guidance - Quick Facts
www.rttnews.com - November 3 at 9:27 AM
Edited Transcript of ANIP earnings conference call or presentation 2-Nov-17 2:30pm GMTEdited Transcript of ANIP earnings conference call or presentation 2-Nov-17 2:30pm GMT
finance.yahoo.com - November 3 at 9:27 AM
ANI Pharmaceuticals, Inc. (ANIP) Given Buy Rating at Canaccord GenuityANI Pharmaceuticals, Inc. (ANIP) Given Buy Rating at Canaccord Genuity
www.americanbankingnews.com - November 2 at 10:30 PM
ANI Pharmaceuticals, Inc. Earnings Advance 45% In Q3ANI Pharmaceuticals, Inc. Earnings Advance 45% In Q3
www.nasdaq.com - November 2 at 4:21 PM
ANI Pharmaceuticals Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year GuidanceANI Pharmaceuticals Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year Guidance
finance.yahoo.com - November 2 at 4:20 PM
ANI posts 3Q profitANI posts 3Q profit
finance.yahoo.com - November 2 at 4:20 PM
ANI Pharmaceuticals, Inc. (ANIP) Issues Quarterly  Earnings ResultsANI Pharmaceuticals, Inc. (ANIP) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 2 at 3:07 PM
ANI Pharmaceuticals, Inc. (ANIP) Issues FY17 Earnings GuidanceANI Pharmaceuticals, Inc. (ANIP) Issues FY17 Earnings Guidance
www.americanbankingnews.com - November 2 at 9:22 AM
Critical Comparison: United Therapeutics Corporation (UTHR) and ANI Pharmaceuticals (ANIP)Critical Comparison: United Therapeutics Corporation (UTHR) and ANI Pharmaceuticals (ANIP)
www.americanbankingnews.com - October 26 at 11:18 PM
ANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2017 Financial ResultsANI Pharmaceuticals Schedules Conference Call to Discuss Third Quarter and Year-to-Date 2017 Financial Results
finance.yahoo.com - October 26 at 10:25 AM
ANI Pharmaceuticals, Inc. (ANIP) Scheduled to Post Earnings on WednesdayANI Pharmaceuticals, Inc. (ANIP) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:04 AM
 Brokerages Anticipate ANI Pharmaceuticals, Inc. (ANIP) to Post $0.99 Earnings Per Share Brokerages Anticipate ANI Pharmaceuticals, Inc. (ANIP) to Post $0.99 Earnings Per Share
www.americanbankingnews.com - October 23 at 12:06 AM
Head-To-Head Survey: NovaBay Pharmaceuticals (NBY) and ANI Pharmaceuticals (ANIP)Head-To-Head Survey: NovaBay Pharmaceuticals (NBY) and ANI Pharmaceuticals (ANIP)
www.americanbankingnews.com - October 20 at 8:34 PM
Financial Review: ANI Pharmaceuticals (ANIP) vs. The CompetitionFinancial Review: ANI Pharmaceuticals (ANIP) vs. The Competition
www.americanbankingnews.com - October 18 at 12:12 AM
ANIP Crosses Above Average Analyst TargetANIP Crosses Above Average Analyst Target
www.nasdaq.com - October 16 at 4:44 PM
ETFs with exposure to ANI Pharmaceuticals, Inc. : October 16, 2017ETFs with exposure to ANI Pharmaceuticals, Inc. : October 16, 2017
finance.yahoo.com - October 16 at 4:44 PM
ANI Pharmaceuticals, Inc. (ANIP) Receives Average Recommendation of "Hold" from AnalystsANI Pharmaceuticals, Inc. (ANIP) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 11 at 2:32 AM
Zacks: Analysts Expect ANI Pharmaceuticals, Inc. (ANIP) Will Announce Quarterly Sales of $48.46 MillionZacks: Analysts Expect ANI Pharmaceuticals, Inc. (ANIP) Will Announce Quarterly Sales of $48.46 Million
www.americanbankingnews.com - October 6 at 4:08 PM
 Analysts Anticipate ANI Pharmaceuticals, Inc. (ANIP) Will Post Earnings of $0.99 Per Share Analysts Anticipate ANI Pharmaceuticals, Inc. (ANIP) Will Post Earnings of $0.99 Per Share
www.americanbankingnews.com - October 4 at 4:32 AM
ANI Pharmaceuticals Hidden Value - Seeking AlphaANI Pharmaceuticals' Hidden Value - Seeking Alpha
seekingalpha.com - October 3 at 3:39 PM
ETFs with exposure to ANI Pharmaceuticals, Inc. : October 3, 2017ETFs with exposure to ANI Pharmaceuticals, Inc. : October 3, 2017
finance.yahoo.com - October 3 at 3:39 PM
ANI Pharmaceuticals Inc (ANIP): Can It Deliver A Superior ROE To The Industry?ANI Pharmaceuticals Inc (ANIP): Can It Deliver A Superior ROE To The Industry?
finance.yahoo.com - October 2 at 3:46 PM
ETFs with exposure to ANI Pharmaceuticals, Inc. : September 19, 2017ETFs with exposure to ANI Pharmaceuticals, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 8:57 PM
ANI Pharmaceuticals, Inc. (ANIP) Expected to Post Quarterly Sales of $48.46 MillionANI Pharmaceuticals, Inc. (ANIP) Expected to Post Quarterly Sales of $48.46 Million
www.americanbankingnews.com - September 17 at 7:50 AM
ANI Pharmaceuticals, Inc. (ANIP) Given Consensus Recommendation of "Hold" by BrokeragesANI Pharmaceuticals, Inc. (ANIP) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 16 at 2:46 AM
 Analysts Anticipate ANI Pharmaceuticals, Inc. (ANIP) to Announce $0.99 EPS Analysts Anticipate ANI Pharmaceuticals, Inc. (ANIP) to Announce $0.99 EPS
www.americanbankingnews.com - September 15 at 12:30 PM
Head-To-Head Review: Nabriva Therapeutics plc - (NBRV) vs. ANI Pharmaceuticals (ANIP)Head-To-Head Review: Nabriva Therapeutics plc - (NBRV) vs. ANI Pharmaceuticals (ANIP)
www.americanbankingnews.com - September 12 at 8:28 PM
ETFs with exposure to ANI Pharmaceuticals, Inc. : September 7, 2017ETFs with exposure to ANI Pharmaceuticals, Inc. : September 7, 2017
finance.yahoo.com - September 7 at 3:55 PM
ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
finance.yahoo.com - September 5 at 5:32 PM
ANI Pharma (ANIP) Reports FDA Approval and Launch of Oxycodone Hydrochloride Oral Solution 100 mg/5mLANI Pharma (ANIP) Reports FDA Approval and Launch of Oxycodone Hydrochloride Oral Solution 100 mg/5mL
www.streetinsider.com - September 3 at 1:45 AM
ANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL - PR Newswire (press release)ANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL - PR Newswire (press release)
www.prnewswire.com - September 2 at 3:40 PM
ANI Pharma Reveals Approval And Launch Of Oxycodone Hydrochloride Oral SolutionANI Pharma Reveals Approval And Launch Of Oxycodone Hydrochloride Oral Solution
www.nasdaq.com - September 1 at 4:26 PM
ANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mLANI Pharmaceuticals Announces Approval and Launch of Oxycodone Hydrochloride Oral Solution, 100 mg/5mL
finance.yahoo.com - September 1 at 4:26 PM
ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US : September 1, 2017ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US : September 1, 2017
finance.yahoo.com - September 1 at 4:26 PM
Reviewing OncoSec Medical (ONCS) and ANI Pharmaceuticals (ANIP)Reviewing OncoSec Medical (ONCS) and ANI Pharmaceuticals (ANIP)
www.americanbankingnews.com - August 31 at 4:26 AM
$0.99 EPS Expected for ANI Pharmaceuticals, Inc. (ANIP) This Quarter$0.99 EPS Expected for ANI Pharmaceuticals, Inc. (ANIP) This Quarter
www.americanbankingnews.com - August 28 at 12:20 AM
ANI Pharmaceuticals, Inc. (ANIP) Receives Consensus Rating of "Hold" from AnalystsANI Pharmaceuticals, Inc. (ANIP) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 22 at 2:32 AM
Company Spotlight: ANI Pharmaceuticals - NasdaqCompany Spotlight: ANI Pharmaceuticals - Nasdaq
www.nasdaq.com - August 19 at 2:05 AM
Company Spotlight: ANI PharmaceuticalsCompany Spotlight: ANI Pharmaceuticals
www.rttnews.com - August 18 at 4:02 PM
ANI Pharmaceuticals Valued Cheaply Ahead Of Re-Commercialization Of Corticotropin ProductsANI Pharmaceuticals Valued Cheaply Ahead Of Re-Commercialization Of Corticotropin Products
seekingalpha.com - August 17 at 5:20 PM
ANI Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ANIP) : August 16, 2017ANI Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ANIP) : August 16, 2017
finance.yahoo.com - August 16 at 9:08 PM

Social Media

Financials

Chart

ANI Pharmaceuticals (NASDAQ ANIP) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.